Article

TNF-α Drugs Don’t Appear to Affect Vaccine Responses in RA

A new meta-analysis shows RA treatments have varied effects on patients’ response to flu and pneumonia vaccines.

Hua C, Barnetche T, Combe B, Morel J. Effect of Methotrexate, Anti–Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care & Research. (2014) 66:1016–1026. doi: 10.1002/acr.22246

Methotrexate (MTX) and rituximab (RTX) seem to dampen responses to common immunizations in rheumatoid arthritis (RA) patients -- while tumor necrosis factor-alpha (TNFα) blockers have no apparent effect, according to a new study.

In the first meta-analysis of vaccine response rates in RA patients, French researchers find that MTX lessens the response to pneumococcal vaccines and may impair responses to seasonal flu shots. RTX reduces responses to both.

However, the researchers emphasize that regardless of any treatment effects, vaccines still provide important protection against infection in RA patients.

Despite federal guidelines, they note, only 25% to 30% of RA patients are immunized against flu or pneumonia, due to lack of awareness among health care professionals and patients' distrust of vaccines.

Both flu and pneumonia vaccines use inactivated viruses and pose no risk of viral reactivation. Studies also show no links between vaccination and worsening RA.

The current meta-analysis of 12 studies finds that patients taking MTX show reduced antibody responses to initial and booster doses of polysaccharide and covalent pneumococcal vaccines, and potentially lesser responses to immunization against the H1N1 and H3N2 influenza A strains and one B strain.

Patients given RTX had lower antibody titers in responses to both immunizations, compared to patients not receiving the infusions.

The analysis was limited by the small number of studies reviewed, the investigators say. However, based on their findings and previous research, they suggest that ideally vaccinations should be given before starting MTX. However, they stress, patients can still have a response after beginning treatment.

Pneumonia vaccine can be given before or after RTX infusions, but flu shots can be delayed 2-3 weeks, depending on disease activity.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.